Community Programs, Product Recalls, Quarterly Reports, Product Launches, and
Study Results - Research Report on DaVita, Novo Nordisk, Cynosure, Hospira,
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, November 4, 2013
NEW YORK, November 4, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting DaVita
HealthCare Partners Inc. (NYSE: DVA), Novo Nordisk A/S (NYSE: NVO), Cynosure,
Inc. (NASDAQ: CYNO), Hospira Inc. (NYSE: HSP), and Celsion Corp. (NASDAQ:
CLSN). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
DaVita HealthCare Partners Inc. Research Report
On October 15, 2013, DaVita HealthCare Partners Inc. (DaVita) and a leading
provider of kidney care services announced that the seventh annual Tour
DaVita® raised $1 million for The Kidney TRUST, a 501(c)(3) independent
nonprofit organization that seeks to reduce the progression of chronic kidney
disease through a no-cost, rapid screening in non-medical settings. Gloria
Upchurch, Program Manager of The Kidney TRUST, commented, "The funds from this
year's Tour DaVita will go a long way in supporting our mission." Upchurch
added, "We will be able to continue helping communities around the country
better understand their kidney health, including kidney disease risk factors."
The Full Research Report on DaVita HealthCare Partners Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
Novo Nordisk A/SResearch Report
On October 25, 2013, Novo Nordisk A/S (Novo Nordisk) announced the recall of
certain batches of its prefilled insulin product NovoMix30 FlexPen in Austria,
Belgium, Czech Republic, Denmark, France, Germany, Iceland, Luxemburg,
Netherlands, Norway, and Slovakia. According to Novo Nordisk, a quality
control conducted by the Company showed that a small percentage (0.14%) of the
products in these batches do not meet the specifications for insulin strength,
which may lead to the patient's blood sugar level becoming higher or lower
than expected. Novo Nordisk reported that three batches of NovoMix30 Penfill
are being recalled in Ireland and UK and stated that other countries in the EU
might have also received the affected batches through parallel distribution.
The Full Research Report on Novo Nordisk A/S - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
Cynosure, Inc. Research Report
On October 29, 2013, Cynosure, Inc. (Cynosure) released its Q3 2013 results.
Cynosure registered revenues of $60.7 million in Q3 2013, up 63.7% YoY. The
Company posted a net loss of $1.3 million in Q3 2013, compared to a net income
of $3.4 million in Q3 2012. Cynosure reported diluted loss per share of $0.06
in Q3 2013, compared to diluted earnings per share of $0.25 in Q3 2012.
Michael Davin, Cynosure's Chairman, CEO, and President, said, "Our first full
quarter as a combined company demonstrated the complementary nature of the
Cynosure and Palomar businesses, the breadth of our laser- and light-based
aesthetic product lines and our strong global distribution capabilities."
Davin continued, "Primarily related to the acquisition of Palomar,
third-quarter 2013 laser revenues were up 62% to $50.1 million compared with
$31.0 million for the same period of 2012, reflecting growth in both North
American and international distribution channels." The Full Research Report on
Cynosure, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
Hospira Inc. Research Report
On October 23, 2013, Hospira Inc. (Hospira) announced the launch of the Q core
Sapphire infusion system in the US, representing a major step in the
advancement of the Company's global device strategy. Dr. Boaz Eitan, CEO of Q
Core Medical, commented, "We are proud to make this important step forward
together with Hospira and launch our Sapphire system in the US market." Eitan
added, "This is yet another successful stage in the international cooperation
between the companies, and we believe that the combination of our technology
with Hospira's excellent customer support and in-depth experience in the U.S.
market will begin a new era in infusion solutions for our customers." The Full
Research Report on Hospira Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
Celsion Corp. Research Report
On October 24, 2013, Celsion Corp. (Celsion) announced that the latest overall
survival data from its post-hoc analysis of results from the Phase III HEAT
Study of ThermoDox supports continued clinical development through a
prospective pivotal Phase III Study, subject to regulatory review and
agreement. Michael H. Tardugno, Celsion's President and CEO, stated, "Equally
important is that the data supporting our continued development program has
been carefully reviewed by our HEAT Study principal investigators,
international liver cancer experts, former FDA reviewers and independent
statisticians." Tardugno continued, "We will present these findings in detail
to the U.S Food and Drug Administration during the fourth quarter and we will
work with the Agency on the best path forward in a pivotal study." The Full
Research Report on Celsion Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
Press spacebar to pause and continue. Press esc to stop.